Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a biotechnology company developing immune-activating treatments for cancer. Its proprietary Boltbody platform combines tumor-targeting antibodies with immune-stimulating linker-payloads in antibody conjugates called ISACs. The company is focused on clinical development of BDC-4182, a claudin 18.2-targeting ISAC being studied in a Phase 1 dose-escalation trial in people with gastric or gastroesophageal junction cancer. Other programs include CEA and PD-L1 ISACs and BDC-3042, a dectin-2 agonist antibody; these programs are on hold, and BDC-3042 development is paused. Bolt works with other companies under development and license collaborations, which may include research funding, milestone payments and royalties. It relies on third-party contract development and manufacturing organizations to produce and test clinical materials. Bolt is headquartered in Redwood City, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Bolt (BOLT) reported Q3 EPS of -$2.25, beating estimates by $1.27, with revenue of $450K, exceeding expectations of $426.25K. The stock is up 76.42% in 3 months and 29.32% in 12 months. InvestingPro rates Bolt's financial health as 'fair performance'.
Bolt Biotherapeutics reported Q3 2026 with no collaboration revenue and a net loss of $4.4M, down from $7.1M a year earlier. The company acquired Prana Therapies and raised $120M in October, funding operations into 2028. PRA-216 entered Phase 2 trials, with initial data expected in Q2 2027.
Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary de
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning BOLT (Bolt Biotherapeutics, Inc.). Coverage has been balanced: 2 bullish, 1 neutral, and 2 bearish.
Recent BOLT coverage spans earnings, corporate actions and mergers & acquisitions.
In the last 30 days, BOLT insiders filed 1 SEC Form 4 transaction — 1 purchase ($319K) and no sales. The most active reporter was Coastlands Capital LP with 1 filing.
Earnings beat may drive short-term buying interest.
The large private placement provides runway but dilutes existing shareholders; earnings miss may pressure the stock short-term, while the cash infusion could support future upside.
The financing and acquisition provide significant capital and pipeline expansion, likely supporting a price increase.
The insider purchase may create modest buying pressure as it signals confidence from a 10% owner.
Bolt’s planned Level 4-capable robotaxi rollout is a near-to-mid-term catalyst contingent on regulatory approval and execution.
AlphAI scores every news story that mentions BOLT with an AI model for sentiment and relevance, and aggregates insider trades from Bolt Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bolt (BOLT) reported Q3 EPS of -$2.25, beating estimates by $1.27, with revenue of $450K, exceeding expectations of $426.25K. The stock is up 76.42% in 3 months and 29.32% in 12 months. InvestingPro rates Bolt's financial health as 'fair performance'.
Bolt Biotherapeutics reported Q3 2026 with no collaboration revenue and a net loss of $4.4M, down from $7.1M a year earlier. The company acquired Prana Therapies and raised $120M in October, funding operations into 2028. PRA-216 entered Phase 2 trials, with initial data expected in Q2 2027.
Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary de
Coastlands Capital LP purchased 50,000 indirectly-held shares of Bolt Biotherapeutics, Inc. (BOLT) at $6.38 ($0.32M total) on 2026-11-09.
Europe's autonomous vehicle sector is advancing with robotaxi and automated driving programs from companies like Bolt, Lucid, Mercedes-Benz, Volkswagen, Volvo, and Einride. Bolt plans a 25,000-vehicle robotaxi program in Europe, starting in Madrid in 2027, using Nvidia's technology. Volkswagen is developing an autonomous ID. Buzz van, while Mercedes-Benz and Volvo are integrating Nvidia's systems for higher automation levels. Einride is working on autonomous trucking.
Bolt Biotherapeutics (BOLT) rose 66% after a reverse merger and $120M private placement. Lycia Therapeutics (LYCA) gained 67% in its IPO debut, raising $317.5M. Lucid Diagnostics (LUCD) climbed 28% on Medicare reimbursement for its EsoGuard test. Genmab (GMAB) advanced 10% after positive Phase 3 ovarian cancer trial results.
Bolt Biotherapeutics (BOLT) appointed Sheila Gujrathi as a Class II director and chief strategy officer, effective October 23, 2026. Gujrathi is the founder and CEO of Prana Therapies and has extensive biotech leadership experience. The appointment follows the company's Merger Agreement.
Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-lif
Bolt Biotherapeutics (BOLT) acquired Prana Therapies in a reverse merger, raising $120M with potential for $60M more. Post-merger, Prana shareholders own 51.7% of Bolt. The combined company will advance Prana's INSPIRE platform, with Phase 2 data expected in Q2 2027. Sheila Gujrathi, Prana's co-founder, joins Bolt's board.
Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Lease Agreement Amendment On October 1, 2026, Bolt Biotherapeutics, Inc. (the “Company”) entered into the Second Amendment to Lease (the “Second Lease Amendment”) with HCP LS Redwood City LLC, as landlord (the “Landlord”). The
